IFM Investors Pty Ltd Buys 2,671 Shares of The Cooper Companies, Inc. $COO

IFM Investors Pty Ltd raised its stake in shares of The Cooper Companies, Inc. (NASDAQ:COO) by 6.9% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 41,609 shares of the medical device company’s stock after purchasing an additional 2,671 shares during the quarter. IFM Investors Pty Ltd’s holdings in Cooper Companies were worth $2,961,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also bought and sold shares of COO. Goldman Sachs Group Inc. lifted its position in Cooper Companies by 17.0% during the first quarter. Goldman Sachs Group Inc. now owns 4,734,327 shares of the medical device company’s stock valued at $399,340,000 after purchasing an additional 686,751 shares during the last quarter. Millennium Management LLC raised its stake in shares of Cooper Companies by 36.0% during the first quarter. Millennium Management LLC now owns 2,577,416 shares of the medical device company’s stock worth $217,405,000 after acquiring an additional 682,166 shares in the last quarter. Nuveen LLC purchased a new position in shares of Cooper Companies during the first quarter worth approximately $55,367,000. Alecta Tjanstepension Omsesidigt raised its stake in shares of Cooper Companies by 60.7% during the second quarter. Alecta Tjanstepension Omsesidigt now owns 1,349,500 shares of the medical device company’s stock worth $96,030,000 after acquiring an additional 509,800 shares in the last quarter. Finally, Select Equity Group L.P. raised its stake in shares of Cooper Companies by 185.0% during the first quarter. Select Equity Group L.P. now owns 749,050 shares of the medical device company’s stock worth $63,182,000 after acquiring an additional 486,241 shares in the last quarter. 24.39% of the stock is currently owned by institutional investors.

Cooper Companies Stock Performance

Shares of Cooper Companies stock opened at $68.00 on Tuesday. The firm’s 50-day moving average is $70.54 and its 200 day moving average is $74.81. The stock has a market cap of $13.52 billion, a price-to-earnings ratio of 33.50, a PEG ratio of 1.79 and a beta of 0.97. The Cooper Companies, Inc. has a 1 year low of $61.78 and a 1 year high of $111.44. The company has a debt-to-equity ratio of 0.29, a current ratio of 2.12 and a quick ratio of 1.24.

Cooper Companies (NASDAQ:COO) last released its earnings results on Wednesday, August 27th. The medical device company reported $1.10 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.07 by $0.03. The company had revenue of $1.06 billion during the quarter, compared to analyst estimates of $1.06 billion. Cooper Companies had a net margin of 10.08% and a return on equity of 9.82%. The firm’s quarterly revenue was up 5.7% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.96 EPS. Cooper Companies has set its Q4 2025 guidance at 1.100-1.140 EPS. FY 2025 guidance at 4.080-4.120 EPS. Sell-side analysts anticipate that The Cooper Companies, Inc. will post 3.98 EPS for the current fiscal year.

Cooper Companies announced that its board has authorized a share repurchase program on Wednesday, September 17th that allows the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization allows the medical device company to buy up to 15.4% of its stock through open market purchases. Stock repurchase programs are typically an indication that the company’s leadership believes its stock is undervalued.

Insider Buying and Selling

In other Cooper Companies news, CEO Albert G. White III bought 10,000 shares of Cooper Companies stock in a transaction on Friday, September 5th. The shares were acquired at an average price of $68.39 per share, for a total transaction of $683,900.00. Following the completion of the purchase, the chief executive officer directly owned 226,151 shares in the company, valued at approximately $15,466,466.89. This trade represents a 4.63% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Brian G. Andrews bought 1,525 shares of Cooper Companies stock in a transaction on Tuesday, September 2nd. The stock was acquired at an average price of $65.68 per share, for a total transaction of $100,162.00. Following the purchase, the executive vice president owned 22,191 shares of the company’s stock, valued at approximately $1,457,504.88. This trade represents a 7.38% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have purchased 15,975 shares of company stock valued at $1,079,566 in the last three months. Corporate insiders own 1.98% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the stock. Loop Capital set a $100.00 price target on shares of Cooper Companies in a research note on Tuesday, June 17th. BNP Paribas raised shares of Cooper Companies from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, July 22nd. Needham & Company LLC reissued a “buy” rating and set a $94.00 price target on shares of Cooper Companies in a research note on Thursday, August 28th. UBS Group raised shares of Cooper Companies to a “buy” rating in a research note on Tuesday, June 17th. Finally, Wall Street Zen downgraded shares of Cooper Companies from a “buy” rating to a “hold” rating in a research note on Saturday, July 12th. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $86.64.

Cooper Companies Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.